The FY2024 (Dec) proxy of Bicycle Therapeutics names 19 peer companies for pay. Among Bicycle Therapeutics and these peers, CEO pay was the lowest of 9 and total shareholder return was 6th highest of 9.
9th highest of 9in Bicycle Therapeutics and its pay peers, FY2024 (Dec) by CEO pay:
$4.9M$18.8M
6th highest of 9in Bicycle Therapeutics and its pay peers, FY2024 (Dec) by total shareholder return:
$47$271
Pay peer group, FY2024 (Dec) proxy
| TG Therapeutics | ||
| Ionis Pharmaceuticals | ||
| Intellia Therapeutics | ||
| Arvinas | ||
| Arcus Biosciences | ||
| Agios Pharmaceuticals | ||
| Beam Therapeutics | ||
| Cogent Biosciences | ||
| Blueprint Medicines Corporation | Not disclosed | Not disclosed |
| Deciphera Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| ImmunoGen, Inc. | Not disclosed | Not disclosed |
| Karuna Therapeutics, Inc. | Not disclosed | Not disclosed |
| Revance Therapeutics, Inc. | Not disclosed | Not disclosed |
| Rhythm Pharmaceuticals | Not disclosed | Not disclosed |
| Sage Therapeutics, Inc. | Not disclosed | Not disclosed |
| SpringWorks Therapeutics, Inc. | Not disclosed | Not disclosed |
| Syndax Pharmaceuticals | Not disclosed | Not disclosed |
| Xencor | Not disclosed | Not disclosed |
| Zentalis Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
19 companies
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.